Increased RTN3 phenocopies nonalcoholic fatty liver disease by inhibiting the AMPK-IDH2 pathway. 2023

Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
Department of Nephrology Xiangya Hospital Central South University Changsha China.

Reticulon 3 (RTN3), an endoplasmic reticulum protein, is crucial in neurodegenerative and kidney diseases. However, the role of RTN3 in liver tissues has not been described. Here, we employed public datasets, patients, and several animal models to explore the role of RTN3 in nonalcoholic fatty liver disease (NAFLD). The underlying mechanisms were studied in primary hepatocytes and L02 cells in vitro. We found an increased expression of RTN3 in NAFLD patients, high-fat diet mice, and oxidized low-density lipoprotein-treated L02 cells. The RTN3 transgenic mice exhibited the phenotypes of fatty liver and lipid accumulation. Single-cell RNA sequencing analysis indicated that increased RTN3 might induce mitochondrial dysfunction. We further showed this in primary hepatocytes, the L02 cell line, and the Caenorhabditis elegans strain. Mechanistically, RTN3 regulated these events through its interactions with glucose-regulated protein 78 (GRP78), which further inhibited the adenosine 5 monophosphate-activated protein kinase (AMPK)-isocitrate dehydrogenase 2 (IDH2) pathway. In the end, knockout of RTN3 relieved fatty liver and mitochondrial dysfunction. Our study indicated that RTN3 was important in NAFLD and lipid catabolism and that an increase in RTN3 in the liver might be a risk factor for nonalcoholic steatohepatitis and NAFLD.

UI MeSH Term Description Entries

Related Publications

Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
December 2019, World journal of gastroenterology,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
October 2023, European journal of pharmacology,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
January 2015, International journal of clinical and experimental medicine,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
August 2020, Biochemical and biophysical research communications,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
January 2022, Frontiers in physiology,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
August 2023, Experimental & molecular medicine,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
October 2016, American journal of physiology. Endocrinology and metabolism,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
September 2023, Experimental & molecular medicine,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
May 2021, Journal of oleo science,
Hao Huang, and Shuai Guo, and Ya-Qin Chen, and Yu-Xing Liu, and Jie-Yuan Jin, and Yun Liang, and Liang-Liang Fan, and Rong Xiang
January 2024, Diabetes, metabolic syndrome and obesity : targets and therapy,
Copied contents to your clipboard!